Home / Conditions / Hormone Abnormality
Hormone Abnormality: when insurers say no, reviewers often say yes
In 100 published external-review decisions involving hormone abnormality, independent physician reviewers overturned the insurer’s denial 52% of the time.
Published decisions
100
2001–2026
Overturned
52%
52 denials reversed
Most-fought treatments for hormone abnormality
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Hormones | 74 | 50% |
| Weight Control | 8 | 50% |
| Diabetic Medication | 4 | 75% |
| Lab Work | 3 | 33.3% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 93 | 53.8% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 7 | 28.6% |
Typical time to a decision
19 days
Most land between 12 and 21 days
Handled as urgent
16%
Expedited when a delay would cause harm
Recent direction
Rising
46.7% → 50% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Wegovy solution auto-injector. Obesity is a disease associated with a significant increase in mortality and many health risks, including type 2 diabetes mellitus, polycystic ovarian syndrome, hypertension, dyslipidemia, and coronary heart disease. Weight loss in patients with overweight and obesity is associated with a reduction in mortality. According to a current guidelines, patients with overweight or obesity should be advised to follow a structured and comprehensive lifestyle intervention program designed for weight loss that includes a healthy meal plan, physical activity, and behavioral intervention.
Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for components of the bilateral breast implant removal and replacement procedures.Breast cancer has become one of the most common malignancies in women worldwide. BRCA1 (BReast CAncer gene 1) and BRCA2 (BReast CAncer gene 2) are genes that produce proteins that help repair damaged deoxyribonucleic acid (DNA). Patients who inherit harmful variants in one of these genes have increased risks of several cancers most notably breast and ovarian cancer, but also several additional types of cancer. A review of medical literature reveals that patients with BRACA2 mutation have a genetic predisposition to breast cancer, an increase of 45-69% compared with the general population.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement and prospective authorization and coverage for Xyosted 100 mg/0.5 mL auto-injector. Lunenfeld and colleagues explain that male hypogonadism is defined by low levels of serum testosterone. Hypogonadism should be treated with testosterone therapy to induce and maintain secondary sex characteristics and to correct symptoms of testosterone deficiency, and if left untreated, may adversely affect multiple organ functions and quality of life. Testosterone treatment options include testosterone cypionate or testosterone enanthate by intramusclar injection, testosterone patch, topical transdermal gels, axillary foam, buccal testosterone tablets, testosterone pellets, injectable long-acting testosterone undecanoate in oil, and nasal testosterone gel.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Ozempic. Government regulatory guidelines approve the use of Ozempic (semaglutide) for the lowering of blood sugar in patients with type 2 diabetes mellitus. Researchers report that clinical research showed that when Ozempic was added to other standard therapies for patients with a history of type 2 diabetes mellitus, these patients saw a substantial decrease in their A1C levels. The A1C cut-off goal for the trial was set at greater than or equal to 7.0 and non-diabetic patients were excluded from the research trial. While the trial did show evidence of weight loss in patients with type 2 diabetes on Ozempic, Ozempic is not currently approved by the FDA for weight loss.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for hormone abnormality was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.